A CHO cell line and a process for the production of recombinant human urokinase in its low molecular weight form (rh-LMW-uPA) via said cell line are described. The process has high productivity and allows the production of low molecular weight urokinase with improved characteristics in terms of safety, quality and stability.
The use of a probiotic, in particular an Enterococcus faecium strain named SF68, for the treatment of disorders characterized by alterations of the intestinal mucosa, particularly inflammations associated with altered intestinal permeability is described.
Enterococcus faeciumEnterococcus faecium strain NCIMB 10415 which is named SF68® as probiotic active ingredient, in combination with butyric acid or a salt thereof to increase the enterocyte's health and consequently the wellness of pets and livestock is described.
01 - Chemical and biological materials for industrial, scientific and agricultural use
31 - Agricultural products; live animals
Goods & Services
Microbiotic organisms, other than for medical use; Cultures, other than for medical or veterinary use; Chemical preparations for scientific purposes, other than for medical or veterinary use; Bacteriological preparations, other than for medical and veterinary use; Bacteriological cultures [other than for medical and veterinary use]; Biological preparations, other than for medical or veterinary purposes; Preparations of microorganisms, other than for medical and veterinary use. Foodstuffs for domestic animals; Animal feed preparations; Synthetic animal feed; Formula animal feed.
he present invention relates to a co-crystal of Dasatinib with triethyl citrate, processes for its preparation, pharmaceutical compositions thereof and its use in the treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The present invention relates to co-crystals of Dasatinib with phenolic compounds selected among resorcinol, vanillyl alcohol, 4-ethoxyphenol, carvacrol and p-cresol, processes for their preparation, pharmaceutical compositions containing them and their use in treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemical products for use in industry, cultures of
micro-organisms, except for medical or veterinary purposes;
probiotic bacteria and probiotic bacteria cultures, not for
medical or veterinary use; probiotic bacteria and probiotic
bacteria cultures as components of foodstuffs for humans and
animals, not for medical or veterinary use. Cultures of micro-organisms, probiotic bacteria and
probiotic bacteria cultures as components of pharmaceutical
and veterinary preparations; cultures of micro-organisms,
probiotic bacteria and probiotic bacteria cultures for
medical and veterinary purposes; dietetic substances for
medical and veterinary use.
5-methyl-(5,6,7,8)-tetrahydrofolic acid and a polyol were prepared by lyophilization or spray-drying. These products were found to be stable compared with the active ingredient alone or the mixture of the same components prepared by means of other methodologies.
C07D 475/04 - Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present invention relates methods of preparing particles of tiotropium bromide particularly useful for inhalationdelivery, the particles obtained from such methods, and their use in pharmaceutical compositions for treatment of respiratory disorders, such as COPD (chronic obstructive pulmonary disease) and asthma.
A continuous process for the alkylation of tertiary amines and, in particular, to a continuous process for the quaternization of cyclic tertiary amines useful for the preparation of cyclic quaternary ammonium salts with high purity is described.
A continuous process for the alkylation of tertiary amines and, in particular, to a continuous process for the quaternization of cyclic tertiary amines useful for the preparation of cyclic quaternary ammonium salts with high purity is described.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Cultures of microorganisms, probiotic bacteria and probiotic bacterial cultures, as ingredients for veterinary preparations.
(2) Probiotic bacterial cultures, for medical purposes; dietetic probiotic bacteria and probiotic bacterial cultures for medical use.
(3) Probiotic bacteria and probiotic bacterial cultures for scientific research; probiotic bacteria and probiotic bacterial cultures for use in the manufacture of foodstuffs for humans and for animals; cultures of microorganisms, probiotic bacteria and probiotic bacterial cultures, as ingredients for pharmaceutical and veterinary preparations; cultures of microorganisms, probiotic bacteria and probiotic bacterial cultures, for medical and veterinary purposes; dietetic probiotic bacteria and probiotic bacterial cultures for medical and veterinary use.
14.
Process for the preparation of stable, amorphous calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid
A process for the preparation of the stable, amorphous calcium salt of (6S)—N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula V,
and a stable, amorphous calcium salt of (6S)—N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula V are provided.
C07D 475/04 - Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Micro-organism cultures, except for medical or veterinary
purposes; probiotic bacteria and probiotic bacteria
cultures, except for medical or veterinary purposes;
probiotic bacteria and probiotic bacteria cultures as
ingredients for foods for humans and animals, except for
medical or veterinary purposes. Microorganism cultures, probiotic bacteria and probiotic
bacteria cultures as components for pharmaceutical and
veterinary preparations; microorganism cultures, probiotic
bacteria and probiotic bacteria cultures for medical or
veterinary purposes; dietetic substances for use in medicine
and veterinary medicine.
There is provided a stable, crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula IV,
This compound belongs to the family of reduced folates which are useful in vitaminic and oncological field.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemicals, cultures of microorganisms other than for
medical and veterinary use, protein (raw material). Pharmaceutical preparations, cultures of microorganisms for
pharmaceutical, medical and veterinary use.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemicals, namely, chemical preparations for scientific purposes, cultures of microorganisms other than for medical and veterinary use, protein arrays and nucleotide arrays for scientific and medical research [ Pharmaceutical preparations for the treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; cultures of microorganisms for pharmaceutical, medical and veterinary use ]
19.
PROCESS FOR PREPARING THE STABLE, AMORPHOUS CALCIUM SALT OF (6S)-N(5)-METHYL-5,6,7,8-TETRAHYDROFOLIC ACID
The present invention relates to a process for preparing the stable, amorphous calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid. The present invention also relates to a process for preparing stable, crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid. The present invention also relates to a process for preparing an aqueous solution of the calcium salt of (6S)-N(5)-methy1-5,6,7,8-tetrahydrofolic acid.
C07D 475/04 - Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
20.
A PROCESS FOR THE PREPARATION OF THE STABLE, AMORPHOUS CALCIUM SALT OF (6S)-N(5)-METHYL-5, 6, 7, 8-TETRAHYDROFOLIC ACID
The present invention relates to a process for preparing the stable, amorphous calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid. The present invention also relates to a process for preparing stable, crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid. The present invention also relates to a process for preparing an aqueous solution of the calcium salt of (6S)-N(5)-methy1-5,6,7,8-tetrahydrofolic acid.
C07D 475/04 - Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
21.
PROCESS FOR REGIOSELECTIVE N(5)-FORMYLATION OF (6S)-5,6,7,8-TETRAHYDROPTEROIC ACID AND DERIVATIVES THEREOF
The process according to the invention for regioselective N(5)-formylation of (6S)-5,6,7,8-tetrahydropteroic acid and derivatives thereof which are defined in formula (I) is characterized in that an aqueous buffer solution having a pH of from 6.5 to 7.5 is added to a mixture of a compound of the formula (I), an antioxidant and a formyl donor in a reaction vessel; an inert gas is blown through the resulting suspension; then an aqueous solution of a base is added dropwise or in portions with constant stirring until a clear solution which has a pH between 6.5 and 8.3 is formed; then a recombinant monofunctional glutamate formyl transferase, abbreviated to rGFT, i.e. the enzyme, is added in an aqueous buffer solution defined above; then the temperature is increased to a range of 30°C to 45°C and the reaction mixture is allowed to react until at least 95% of the formyl has been transferred from the formyl donor to the compound of the formula (I), - then the resulting reaction mixture is cooled to a temperature of from 0°C to 5°C; then an aqueous solution of a mineral acid is added dropwise until a pH of from 2.7 to 3.1 has been attained, which precipitates out the crude compound of the formula (II); the stirring is continued over at least 1 hour in order to complete the abovementioned precipitation, and the crude compound of the formula (II) is obtained.
C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Cultures of microorganisms for scientific research; probiotic bacteria and probiotic bacterial cultures for scientific research; probiotic bacteria and probiotic bacterial cultures for use in the manufacture of foodstuffs [ for humans or ] for animals Cultures of microorganisms, probiotic bacteria and probiotic bacterial cultures, as ingredients for [ pharmaceutical or ] veterinary preparations; cultures of microorganisms, probiotic bacteria and probiotic bacterial cultures, [ for medical or ] veterinary purposes; dietetic probiotic bacteria and probiotic bacterial cultures for medical or veterinary use
23.
A STABLE SOLUTION CONTAINING BESIDE WATER EITHER (6S)-SODIUM-FOLINATE OR (6S)-POTASSIUM-FOLINATE IN AN AMOUNT FROM 2% BY WEIGHT TO 6% BY WEIGHT
The inventive method for the production of crystalline (6RS)-N(5)-formyl- 5,6,7,8-tetrahydrofolic acid or amorphic (6S)-N(5)-formyl-5,6,7,8- tetrahydrofolic acid is characterized in that an aqueous solution of (6RS)- or (6S)-calcium folinate, which has a temperature of 40 ~C to 50 ~C, and an aqueous solution of hydrochloric acid or acetic acid are added to stirred water having a temperature of 2 ~C to 12 ~C, such that the temperature is kept at 2 ~C to 12 ~C in the mixture thus obtained when the two above-mentioned solutions are added and the pH value is kept at 2,5 to 3,5, the solid thus arising is isolated by means of filtration or centrifugation, the solid is initially washed with cold water and then with an aqueous organic solvent, and the washed solid, i.e. crystalline (6RS)-N(5)-formyl-5,6,7,8-tetrahydrofolic acid or amorphous (6S)-N(5)-formyl-5,6,7,8-tetrahydrofolic acid is dried at reduced pressure and obtained.
C07D 475/04 - Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
31 - Agricultural products; live animals
Goods & Services
Cultures of microorganisms; probiotic bacteria and probiotic bacterial cultures; probiotic bacteria and probiotic bacterial cultures as ingredients for foodstuffs for humans or for animals. Cultures of microorganisms, probiotic bacteria and probiotic bacterial cultures, as ingredients for pharmaceutical or veterinary or dietetic formulations; cultures of microorganisms, probiotic bacteria and probiotic bacterial cultures, for medical or veterinary or dietetic purposes; dietetic substances for medical or veterinary use. Feedstuffs for animals; supplements for feedstuffs for animals; micro-organism cultures for animal feed supplementation; micro-organism cultures for feeding to animals; animal feeds and animal feed supplements containing live micro-organisms.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Produits pharmaceutiques, vétérinaires et hygiéniques;
substances diététiques à usage médical, aliments pour bébés;
emplâtres, matériel pour pansements; matières pour plomber
les dents et pour empreintes dentaires; désinfectants;
produits pour la destruction des animaux nuisibles;
fongicides, herbicides.